XML 94 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements - Collaborative Arrangements Narrative (Details)
€ / shares in Units, € in Millions, shares in Millions, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jul. 31, 2018
EUR (€)
Jul. 19, 2018
USD ($)
Jan. 01, 2018
USD ($)
Mar. 31, 2016
€ / shares
shares
Jan. 31, 2016
USD ($)
Collaborative Arrangements                  
Prepaid and other current assets   $ 1,606 $ 1,661       $ 1,757    
Research and development expenses   5,018 3,734 $ 5,098          
Percentage of Costs Responsible       80.00%          
Goodwill   4,117 4,159            
Other Research and Development Expense   278              
Cost of goods sold   $ 4,853 4,371 $ 4,261          
Document Fiscal Year Focus   2018              
Collaboration Agreement, Initial Consideration Transferred   $ 474 0 0          
Gadeta [Member]                  
Collaborative Arrangements                  
Collaborative Arrangement-Potential Option Payout Upon Exercise | €         € 300        
Indefinite-lived Intangible Assets Acquired     $ 117            
Noncontrolling Interest in Variable Interest Entity           $ 82      
Goodwill           $ 0      
Janssen Pharmaceuticals [Member]                  
Collaborative Arrangements                  
Purchase price of goods less specified amount, maximum percentage     30.00%            
Cost of goods sold   608 $ 561 459          
Japan Tobacco                  
Collaborative Arrangements                  
Finite-lived Intangible Assets Acquired   550              
Prepaid and other current assets   9              
Royalty Expense   452 $ 400 282          
Revenue Collaboration Agreement, Payment Obligation   559              
Revenue Collaboration Agreement, Initial Consideration Transferred   194              
Noncash or Part Noncash Acquisition, Intangible Assets Acquired   365              
Galapagos [Member]                  
Collaborative Arrangements                  
License Fee Payment $ 300                
Available-for-sale Securities, Equity Securities, Noncurrent 425                
Share Price | € / shares               € 58  
Investment Owned, Balance, Shares | shares               6.8  
Research and development expenses $ 68     $ 60          
Equity Method Investments   622              
Percentage of Costs Responsible       20.00%          
Galapagos [Member] | Minimum [Member]                  
Collaborative Arrangements                  
Potential Future Milestone Payment, Tiered Royalty Payment                 20.00%
Galapagos [Member] | Maximum [Member]                  
Collaborative Arrangements                  
Potential Future Milestone Payment, Tiered Royalty Payment                 30.00%
Bristol-Myers-Squibb [Member]                  
Collaborative Arrangements                  
Cost of goods sold   $ 198              
Development And Regulatory Milestones-Based [Member] | Galapagos [Member]                  
Collaborative Arrangements                  
Potential Future Milestone Payment                 $ 755
Sales-Based Milestones [Member] | Galapagos [Member]                  
Collaborative Arrangements                  
Potential Future Milestone Payment                 $ 600
Galapagos [Member]                  
Collaborative Arrangements                  
Collaboration Arrangement Investment in Counterparty Ownership Percentage               14.75%